Heat Biologics (HTBX) Posts Q3 Loss of 46c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results
November 14, 2014 7:30 AM ESTDURHAM, N.C., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today its financial results for the third quarter ended September 30, 2014 and outlined key highlights of its lead clinical development programs.
THIRD QUARTER AND RECENT CLINICAL DEVELOPMENT HIGHLIGHTS:
Vesigenurtacel-L (HS-410) for the treatment of bladder... More
